• 1
    Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 10715.
  • 2
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 70514.
  • 3
    Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 2718.
  • 4
    Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, treatment, and management of hepatitis C: an update. AASLD Guidelines. Hepatology 2009; 49: 133574.
  • 5
    Pradat P, Tillmann HL, Sauleda S, et al. ; For the HENCORE group. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepatitis 2007; 14: 55663.
  • 6
    Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011; 40: 11828.
  • 7
    Michaels AJ, Nelson DR. New therapies in the management of hepatitis C virus. Curr Opin Gastroenterol 2010; 26: 196201.
  • 8
    Rocca L, Yawn BP, Wollan P, Kim WR. Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat. Ann Fam Med 2004; 2: 11624.
  • 9
    Yawn BP, Wollan P, Gazzuola L, Kim WR. Diagnosis and 10-year follow-up of a community-based hepatitis C cohort. J Fam Pract 2002; 51: 13540.
  • 10
    Beste LA, Straits-Troster K, Zickmund S, Larson M, Chapko M, Dominitz JA. Specialty care and education associated with greater disease-specific knowledge but not satisfaction with care for chronic hepatitis C. Aliment Pharmacol Ther 2009; 30: 27582.
  • 11
    Jazwinski AB, Muir AJ. Direct-acting antiviral medications for chronic hepatitis C virus infection. Gastroenterol Hepatol (N Y) 2011; 7: 15462.
  • 12
    Gane EJ, Rouzier R, Stedman C, et al. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN a-2a/RBV in hepatitis C patients. J Hepatol 2011; 55: 9729.
  • 13
    Butt AA, Khan UA, McGinnis KA, Skanderson M, Kent Kwoh C. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. J Viral Hepat 2007; 14: 8906.
  • 14
    Neal KR, Ramsay S, Thompson BJ, Irving BJ. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 2007; 56: 1098104.
  • 15
    Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945 to 1965: Recommendations from the centers for disease control and prevention. Ann Intern Med 2012; 157: 17.
  • 16
    Shikiar R, Rentz AM. Satisfaction with medication: an overview of conceptual, methodologic, and regulatory issues. Value Health 2004; 7: 20415.
  • 17
    Weaver M, Patrick DL, Markson LE, Martin D, Federic I, Berger M. Issues in the measurement of satisfaction with treatment. Am J Manag Care 1997; 3: 57994.
  • 18
    Oliver RL. Satisfaction: A Behavioral Perspective on the Consumer. New York: The McGraw-Hill Companies Inc., 1997.
  • 19
    Lee EH, Cheong JY, Cho SW, et al. Development and psychometric evaluation of a chronic liver disease-specific quality of life questionnaire. Hepatology 2008; 23: 2318.
  • 20
    Bayliss M, Gandek B, Bungay KM, Sugano D, Hsu MA, Ware JE. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 1998; 7: 3955.
  • 21
    Flood EM, Beusterien KM, Green H, et al. Psychometric evaluation of the osteoporosis patient treatment satisfaction questionnaire (OPSAT-Q), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal women. Health Qual Life Outcomes 2005; 4: 113.
  • 22
    Woodcock A, Bradley C. Validation of the HIV treatment satisfaction questionnaire (HIVTSQ). Qual Life Res 2001; 10: 51731.
  • 23
    Coyne K, Joshua-Gotlib S, Kimel M, Thompson C, Lewis A, Danilewitz M. Validation of the treatment satisfaction questionnaire for Crohn's Disease (TSQ-C). Dig Dis Sci 2005; 50: 2528.
  • 24
    Szeinbach SL, Baran RW, Bratten J, Jones MP. Psychometric development and validation of the chronic constipation treatment satisfaction questionnaire (CTSAT-Q). Value Health 2009; 12: 100410.
  • 25
    Bazeley P. Qualitative Data Analysis With NVivo. Thousand Oaks, CA: SAGE Publications, 2007.
  • 26
    Nunnally JC, Bernstein IH. Psychometric Theory. New York, NY: McGraw-Hill, 1994.
  • 27
    Bollen KA, Long JJ, eds. Testing Structural Equation Models. Newbury Park, CA: Sage, 1993.
  • 28
    Kline RB. Principles and Practice of Structural Equation Modeling. New York, NY: The Guilford Press, 1998.
  • 29
    Gering DW, Anderson JC. An updated paradigm for scale development incorporating unidimensionality and its assessment. J Mark Res 1988; 15: 18692.
  • 30
    Copay AG, Subach BR, Glassman SD, Polly DW Jr, Schuler TC. Understanding the minimum clinically important difference: a review of concepts and methods. Spine J 2007; 7: 5416.
  • 31
    Garver MS, Mentzer JT. Logistics research methods: employing structural equation modeling to test for construct validity. J Bus Logist 1999; 20: 3357.
  • 32
    Bentler PM, Bonnett DG. Significant tests and goodness-of-fit in the analysis of covariance structures. Psychol Bull 1980; 88: 588606.
  • 33
    Kumar RN, Kirking DM, Hass SL, Atkinson MJ, McKercher PL. The association of consumer expectations, experiences and satisfaction with newly prescribed medications. Qual Life Res 2007; 16: 112736.
  • 34
    Blasiole JA, Shinkunas L, LaBrecque DR, Arnold RM, Zickmund SL. Mental and physical symptoms associated with lower social support for patients with hepatitis C. World J Gastroenterol 2006; 12: 466572.
  • 35
    Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med 2011; 364: 2199207.
  • 36
    Beyer AP, Szeinbach SL, Seoane-Vazquez EC, et al. Assessing the reliability and validity of a newly developed insomnia treatment satisfaction questionnaire (ITSAT-Q). Sleep Med 2010; 11: 76671.
  • 37
    Dworkin RH, Jensen MP, Gould E, et al. Treatment satisfaction in osteoarthritis and chronic low back pain: the role of pain, physical and emotional functioning, sleep, and adverse events. J Pain 2011; 12: 41624.
  • 38
    Khokhar OS, Lewis JH. Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time? Dig Dis Sci 2007; 52: 116876.
  • 39
    Nicolucci A, Cucinotta D, Squatrito S, et al. ; on behalf of the QuoLITy Study Group. Clinical and Social-economic correlates of quality of life and treatment satisfaction is patients with type 2 diabetes. Nutr Metab Cardiovasc Dis 2009; 19:4553.
  • 40
    Butt AA, Wang X, Moore CG. Effect of hepatitis C virus and its treatment on survival. Hepatology 2009; 50: 38792.
  • 41
    Freeman A, Gore G, Law M, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 80916.
  • 42
    Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM Version II) among outpatient pharmacy consumers. Value Health 2005; 8: S924.
  • 43
    World Health Organization. Workbook 6 - Client Satisfaction Evaluations. World Health Organization (WHO), 2000, pp. 9. WHO/MSD/MSB 00.2 g.